Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Ascending Dose Tolerability Study of DG3173

NCT02217488 is registered in ClinicalTrials.gov with Aspireo Pharmaceuticals Limited as lead sponsor.

NCT NCT02217488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02217488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Ascending Dose Tolerability Study of DG3173
Lead sponsor
Aspireo Pharmaceuticals Limited
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
Not reported
Enrollment
72 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy